Literature DB >> 32112811

Incidence of nephrogenic systemic fibrosis after administration of gadoteric acid in patients on renal replacement treatment.

Gaetano Alfano1, Francesco Fontana2, Annachiara Ferrari3, Andrea Solazzo3, Rossella Perrone3, Francesco Giaroni3, Pietro Torricelli4, Gianni Cappelli5.   

Abstract

PURPOSE: Nephrogenic system fibrosis (NSF) is a rare complication detected in patients with renal insufficiency exposed to gadolinium-based contrast agents (GBCAs). The aim of our study is to evaluate the prevalence of NSF in a cohort of patients on renal replacement treatment who underwent GBCA-enhanced magnetic resonance imaging (MRI).
METHOD: We retrospectively reviewed all the charts of kidney transplant (KT) recipients, patients on hemodialysis (HD) and peritoneal dialysis (PD) who received a uniform protocol for contrast material enhanced-MRI with gadoteric acid at our center from January 2004 to December 2017.
RESULTS: Three-hundred forty-four patients (44.1% on HD, 11.3% on PD and 44.4% KT recipients) underwent 551 gadoteric acid-enhanced MRI. The median age of the patients was 58 years (IQR, 45-70 years) and 65.1% were men. Sixty-three patients (18.3%) had skin punch biopsy after integumentary assessment performed by a dermatologist. No cases of NSF were detected after a median follow-up of 4.5 years (IQR, 1.9-8.2 years). During this period of observation, 116 (33.7%) patients died and 11 (3.1%) were lost at follow-up.
CONCLUSIONS: None of the patients exposed to gadoteric acid developed NSF. Our results, in line with more recent studies, suggest that the use of gadoteric acid, a macrocyclic GBCA, appears safe even in chronic kidney disease (CKD) patients receiving dialysis.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Gadolinium; Gadolinium contrast agent; Gadoteric acid; Nephrogenic systemic fibrosis; Renal replacement treatment

Year:  2020        PMID: 32112811     DOI: 10.1016/j.mri.2020.02.012

Source DB:  PubMed          Journal:  Magn Reson Imaging        ISSN: 0730-725X            Impact factor:   2.546


  5 in total

1.  Risk for Nephrogenic Systemic Fibrosis After Exposure to Newer Gadolinium Agents: A Systematic Review.

Authors:  Joseph Lunyera; Dinushika Mohottige; Anastasia-Stefania Alexopoulos; Hilary Campbell; C Blake Cameron; Nicole Sagalla; Timothy J Amrhein; Matthew J Crowley; Jessica R Dietch; Adelaide M Gordon; Andrzej S Kosinski; Sarah Cantrell; John W Williams; Jennifer M Gierisch; Belinda Ear; Karen M Goldstein
Journal:  Ann Intern Med       Date:  2020-06-23       Impact factor: 25.391

Review 2.  Gadolinium-Based Contrast Agents: Updates and Answers to Typical Questions Regarding Gadolinium Use.

Authors:  Benjamin Y C Cheong; James M Wilson; Ourania A Preventza; Raja Muthupillai
Journal:  Tex Heart Inst J       Date:  2022-05-01

3.  Venous Segmental Flow Changes after Superficial Venous Intervention Demonstrating by Quantitative Phase-Contrast Magnetic Resonance Analysis: Preliminary Data from a Longitudinal Cohort Study.

Authors:  Chien-Wei Chen; Yuan-Hsi Tseng; Chih-Chen Kao; Yeh Giin Ngo; Chung-Yuan Lee; Teng-Yao Yang; Yu-Hui Lin; Yao-Kuang Huang
Journal:  J Pers Med       Date:  2022-06-19

Review 4.  Imaging tools for assessment of myocardial fibrosis in humans: the need for greater detail.

Authors:  Summer Hassan; Carolyn J Barrett; David J Crossman
Journal:  Biophys Rev       Date:  2020-07-23

5.  Discriminating Reflux from Non-Reflux Diseases of Superficial Veins in Legs by Novel Non-Contrast MR with QFlow Technique.

Authors:  Yuan-Hsi Tseng; Chien-Wei Chen; Min Yi Wong; Teng-Yao Yang; Bor-Shyh Lin; Hua Ting; Yao-Kuang Huang
Journal:  J Pers Med       Date:  2021-03-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.